{"product_id":"high-density-lipoproteins-structure-metabolism-function-and-therapeutics-hardback-9780470408216","title":"High-Density Lipoproteins; Structure, Metabolism, Function and Therapeutics (Hardback) 9780470408216","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eHigh-Density Lipoproteins\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003eStructure, Metabolism, Function and Therapeutics\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eAnatol Kontush (Author), M. John Chapman (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470408216, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 20 February 2012\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e648 pages\u003cbr\u003e22.6 x 15.5 x 3.8 cm, 1.043 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e“In summary, the need for this book is immense: It is an encyclopedia where everyone working in or near the field can quickly find the fact or reference they need. It is a textbook one can give to a student on the first day in the lab. It is a novel that can be read when running out of controversies in your own field.”  (\u003ci\u003eChemMedChem\u003c\/i\u003e, 1 April 2013)\u003c\/p\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eA complete guide to the role of high-density lipoproteins (HDL) in new and emerging therapies\u003c\/p\u003e \u003cp\u003eWith high-density lipoproteins (HDL) playing an increasing role in cardiovascular disease prevention, there is a growing need for an in-depth look at HDL and its clinical value. This book summarizes the current state of knowledge in the field, providing for the first time a comprehensive, systematic, stylistically coherent, and up-to-date review of the composition, structure, heterogeneity, metabolism, epidemiology, genetics, and function of HDL.\u003c\/p\u003e \u003cp\u003eDivided into three main parts, High-Density Lipoproteins first examines normal HDL particles, then describes defective HDL, and finally addresses the therapeutic normalization of subnormal levels and defective biological activities of this lipoprotein class. The book highlights the functional properties of HDL, which are relevant to the pathophysiology of atherosclerosis and thrombosis, and discusses the compositional and metabolic heterogeneity of HDL particles.\u003c\/p\u003e \u003cp\u003eReaders will come away with a clear understanding of the role of HDL in biological processes, the potential value of functional HDL as a therapeutic target, and how current and emerging therapies are poised to influence the treatment of heart disease in the future.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003ePREFACE xv  \u003cp\u003eACKNOWLEDGMENTS xxxi\u003c\/p\u003e \u003cp\u003eABBREVIATIONS xxxiii\u003c\/p\u003e \u003cp\u003eSECTION 1 NORMAL FUNCTIONAL HIGH-DENSITY LIPOPROTEIN 1\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 COMPOSITION 3\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1.1 Proteome \/ 9\u003c\/p\u003e \u003cp\u003eApolipoproteins \/ 9\u003c\/p\u003e \u003cp\u003e\u003ci\u003eApolipoprotein A-I \/ 9\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eApoA-II \/ 9\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eApoA-IV \/ 9\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eApoA-V \/ 10\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eApoC-I, ApoC-II, ApoC-III, ApoC-IV \/ 12\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eApoD \/ 12\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eApoE \/ 13\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eApoF \/ 14\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eApoH \/ 14\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eApoJ \/ 14\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eApoL-I \/ 15\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eApoM \/ 15\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eOther Apolipoproteins \/ 15\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eEnzymes \/ 16\u003c\/p\u003e \u003cp\u003e\u003ci\u003eLCAT \/ 16\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePON1 and PON3 \/ 16\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePAF-AH (LpPLA2) \/ 17\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eGSPx-3 \/ 18\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eLipid Transfer Proteins \/ 18\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePLTP \/ 18\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eCETP \/ 19\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAcute-Phase Response Proteins \/ 19\u003c\/p\u003e \u003cp\u003e\u003ci\u003eSerum Amyloid A \/ 19\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eOther Proteins \/ 20\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eComplement Components \/ 21\u003c\/p\u003e \u003cp\u003eProteinase Inhibitors and Related Proteins \/ 23\u003c\/p\u003e \u003cp\u003eOther Protein Components \/ 25\u003c\/p\u003e \u003cp\u003e1.2 Lipidome \/ 27\u003c\/p\u003e \u003cp\u003ePhospholipids \/ 27\u003c\/p\u003e \u003cp\u003eSteroids \/ 28\u003c\/p\u003e \u003cp\u003eCholesteryl Esters \/ 28\u003c\/p\u003e \u003cp\u003eTriglycerides \/ 28\u003c\/p\u003e \u003cp\u003eMinor Lipids \/ 28\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 HETEROGENEITY 39\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 Heterogeneity in Physicochemical Properties \/ 42\u003c\/p\u003e \u003cp\u003eHeterogeneity in Density \/ 42\u003c\/p\u003e \u003cp\u003eHeterogeneity in Electrophoretic Mobility \/ 43\u003c\/p\u003e \u003cp\u003eHeterogeneity in Size \/ 45\u003c\/p\u003e \u003cp\u003e2.2 Heterogeneity in Chemical Composition \/ 47\u003c\/p\u003e \u003cp\u003eHeterogeneity in Proteins \/ 47\u003c\/p\u003e \u003cp\u003eHeterogeneity in Lipids \/ 49\u003c\/p\u003e \u003cp\u003e2.3 Relationships Between HDL Subfractions Separated by Different Methods \/ 50\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 STRUCTURE 59\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1 Lipid-Free ApoA-I \/ 59\u003c\/p\u003e \u003cp\u003e3.2 Discoid HDL \/ 62\u003c\/p\u003e \u003cp\u003e3.3 Spherical HDL \/ 66\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 METABOLISM 74\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4.1 Formation and Intravascular Remodeling \/ 74\u003c\/p\u003e \u003cp\u003eABC Transporters \/ 77\u003c\/p\u003e \u003cp\u003e\u003ci\u003eABCA1 \/ 77\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eABCG1 \/ 85\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eEnzymes \/ 86\u003c\/p\u003e \u003cp\u003e\u003ci\u003eLCAT \/ 86\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eLipases \/ 88\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eLipid Transfer Proteins \/ 90\u003c\/p\u003e \u003cp\u003e\u003ci\u003eCETP \/ 90\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePLTP \/ 92\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eReceptors \/ 93\u003c\/p\u003e \u003cp\u003e\u003ci\u003eSR-BI \/ 93\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.2 Catabolism \/ 96\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 EPIDEMIOLOGY 113\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5.1 Epidemiology of HDL-C \/ 113\u003c\/p\u003e \u003cp\u003eHDL-C and Cardiovascular Risk \/ 113\u003c\/p\u003e \u003cp\u003e\u003ci\u003eRelevance Across Multiple Populations and Disease States \/ 116\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eHDL-C and Other Cardiovascular Risk Factors \/ 120\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePrevalence of Low HDL-C \/ 122\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eHDL-C and Cardiovascular Risk in Patients Receiving Statins \/ 123\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eHDL-C and Other Major Diseases \/ 125\u003c\/p\u003e \u003cp\u003e5.2 Epidemiology of HDL-Associated Proteins and Enzymes \/ 126\u003c\/p\u003e \u003cp\u003eApoA-I \/ 126\u003c\/p\u003e \u003cp\u003eOther Apolipoproteins \/ 129\u003c\/p\u003e \u003cp\u003eSAA \/ 130\u003c\/p\u003e \u003cp\u003ePON1 \/ 130\u003c\/p\u003e \u003cp\u003ePAF-AH \/ 131\u003c\/p\u003e \u003cp\u003eOther Enzymes \/ 133\u003c\/p\u003e \u003cp\u003eLipid Transfer Proteins \/ 133\u003c\/p\u003e \u003cp\u003e5.3 Epidemiology of HDL Particle Subpopulations \/ 134\u003c\/p\u003e \u003cp\u003eSeparated by Density \/ 134\u003c\/p\u003e \u003cp\u003eSeparated by Electrophoretic Mobility \/ 135\u003c\/p\u003e \u003cp\u003eSeparated by Composition \/ 135\u003c\/p\u003e \u003cp\u003eSeparated by Size \/ 135\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 GENETICS 161\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6.1 ABC Transporters and Other Receptors \/ 165\u003c\/p\u003e \u003cp\u003eABCA1 \/ 165\u003c\/p\u003e \u003cp\u003eSR-BI \/ 167\u003c\/p\u003e \u003cp\u003eLDL Receptor \/ 167\u003c\/p\u003e \u003cp\u003e6.2 Apolipoproteins \/ 167\u003c\/p\u003e \u003cp\u003eApoA-I \/ 167\u003c\/p\u003e \u003cp\u003eApoA-V \/ 168\u003c\/p\u003e \u003cp\u003eApoC-III \/ 168\u003c\/p\u003e \u003cp\u003eApoE \/ 168\u003c\/p\u003e \u003cp\u003e6.3 Enzymes \/ 169\u003c\/p\u003e \u003cp\u003eLCAT \/ 169\u003c\/p\u003e \u003cp\u003ePON1 \/ 169\u003c\/p\u003e \u003cp\u003eLPL \/ 170\u003c\/p\u003e \u003cp\u003eHepatic Lipase \/ 171\u003c\/p\u003e \u003cp\u003eEndothelial Lipase \/ 171\u003c\/p\u003e \u003cp\u003e6.4 Lipid Transfer Proteins \/ 172\u003c\/p\u003e \u003cp\u003eCETP \/ 172\u003c\/p\u003e \u003cp\u003e6.5 Other Genes \/ 174\u003c\/p\u003e \u003cp\u003e6.6 Gene Interactions \/ 176\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 BIOLOGIC ACTIVITIES 192\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7.1 Cholesterol Efflux Capacity \/ 197\u003c\/p\u003e \u003cp\u003eMechanisms of Cellular Cholesterol Efflux \/ 199\u003c\/p\u003e \u003cp\u003e\u003ci\u003eABCA1-Mediated Efflux \/ 199\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eABCG1-Mediated Efflux \/ 203\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eSR-BI-Mediated Efflux \/ 204\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eOther Pathways \/ 205\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eRole of HDL Components \/ 206\u003c\/p\u003e \u003cp\u003e\u003ci\u003eProteins \/ 206\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eLipids \/ 208\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eFunctional Heterogeneity of HDL \/ 210\u003c\/p\u003e \u003cp\u003e7.2 Antioxidative Activity \/ 213\u003c\/p\u003e \u003cp\u003eMechanisms of Protection Against Oxidative Stress \/ 216\u003c\/p\u003e \u003cp\u003eRole of HDL Components \/ 219\u003c\/p\u003e \u003cp\u003e\u003ci\u003eApolipoproteins \/ 219\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eEnzymes \/ 220\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eLipids \/ 223\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eFunctional Heterogeneity of HDL \/ 224\u003c\/p\u003e \u003cp\u003e7.3 Anti-Inflammatory Activity \/ 226\u003c\/p\u003e \u003cp\u003eMechanisms of Anti-Inflammatory Protection \/ 231\u003c\/p\u003e \u003cp\u003eRole of HDL Components \/ 234\u003c\/p\u003e \u003cp\u003e\u003ci\u003eProteome \/ 234\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eLipidome \/ 235\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eFunctional Heterogeneity of HDL \/ 236\u003c\/p\u003e \u003cp\u003e7.4 Cytoprotective Activity \/ 236\u003c\/p\u003e \u003cp\u003eMechanisms of Cytoprotection \/ 238\u003c\/p\u003e \u003cp\u003eRole of HDL Components \/ 241\u003c\/p\u003e \u003cp\u003e\u003ci\u003eProteome \/ 241\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eLipidome \/ 241\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eFunctional Heterogeneity of HDL \/ 242\u003c\/p\u003e \u003cp\u003e7.5 Anti-Infectious Activity \/ 243\u003c\/p\u003e \u003cp\u003eMechanisms of Protection from Infection \/ 245\u003c\/p\u003e \u003cp\u003eRole of HDL Components \/ 246\u003c\/p\u003e \u003cp\u003e\u003ci\u003eProteome \/ 246\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eLipids \/ 248\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eFunctional Heterogeneity of HDL \/ 248\u003c\/p\u003e \u003cp\u003e7.6 Vasodilatory Activity \/ 249\u003c\/p\u003e \u003cp\u003eMechanisms of Vasodilatory Activity \/ 250\u003c\/p\u003e \u003cp\u003eRole of HDL Components \/ 252\u003c\/p\u003e \u003cp\u003e\u003ci\u003eProteins \/ 252\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eLipids \/ 252\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eFunctional Heterogeneity of HDL \/ 253\u003c\/p\u003e \u003cp\u003e7.7 Antithrombotic Activity \/ 253\u003c\/p\u003e \u003cp\u003eMechanisms of Antithrombotic Effects \/ 256\u003c\/p\u003e \u003cp\u003eRole of HDL Components \/ 257\u003c\/p\u003e \u003cp\u003eFunctional Heterogeneity of HDL \/ 258\u003c\/p\u003e \u003cp\u003e7.8 Antidiabetic Activity \/ 259\u003c\/p\u003e \u003cp\u003eSECTION 2 FUNCTIONALLY DEFECTIVE HDL 305\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 ALTERED COMPOSITION 307\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8.1 Proteome \/ 307\u003c\/p\u003e \u003cp\u003e8.2 Lipidome \/ 311\u003c\/p\u003e \u003cp\u003e8.3 Enzymatic Activities \/ 313\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 ABNORMAL METABOLISM 329\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9.1 Dyslipidemias \/ 329\u003c\/p\u003e \u003cp\u003e9.2 Insulin-Resistant States \/ 337\u003c\/p\u003e \u003cp\u003e9.3 Inflammatory States \/ 339\u003c\/p\u003e \u003cp\u003e9.4 Infectious Diseases \/ 341\u003c\/p\u003e \u003cp\u003e9.5 Cardiovascular Disease \/ 342\u003c\/p\u003e \u003cp\u003e9.6 Post-Prandial State \/ 343\u003c\/p\u003e \u003cp\u003e9.7 Smoking \/ 344\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 IMPAIRED BIOLOGIC ACTIVITIES 360\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10.1 Cholesterol Efflux Capacity \/ 361\u003c\/p\u003e \u003cp\u003eDyslipidemia \/ 361\u003c\/p\u003e \u003cp\u003e\u003ci\u003eRole of HDL Components \/ 364\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eInsulin Resistance \/ 365\u003c\/p\u003e \u003cp\u003e\u003ci\u003eRole of HDL Components \/ 367\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eInflammation \/ 369\u003c\/p\u003e \u003cp\u003eCardiovascular Disease \/ 372\u003c\/p\u003e \u003cp\u003ePathophysiologic Relevance \/ 373\u003c\/p\u003e \u003cp\u003e10.2 Antioxidative Activity \/ 373\u003c\/p\u003e \u003cp\u003eDyslipidemia \/ 373\u003c\/p\u003e \u003cp\u003e\u003ci\u003eRole of HDL Components \/ 374\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eInsulin Resistance \/ 376\u003c\/p\u003e \u003cp\u003e\u003ci\u003eRole of HDL Components \/ 376\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eInflammation \/ 379\u003c\/p\u003e \u003cp\u003eInfection \/ 380\u003c\/p\u003e \u003cp\u003eCardiovascular Disease \/ 380\u003c\/p\u003e \u003cp\u003ePathophysiologic Relevance \/ 381\u003c\/p\u003e \u003cp\u003e10.3 Anti-Inflammatory Activity \/ 382\u003c\/p\u003e \u003cp\u003eDyslipidemia \/ 382\u003c\/p\u003e \u003cp\u003eInsulin Resistance \/ 385\u003c\/p\u003e \u003cp\u003eInflammation \/ 386\u003c\/p\u003e \u003cp\u003eCardiovascular Disease \/ 388\u003c\/p\u003e \u003cp\u003ePathophysiologic Relevance \/ 389\u003c\/p\u003e \u003cp\u003e10.4 Cytoprotective Activity \/ 391\u003c\/p\u003e \u003cp\u003e10.5 Vasodilatory Activity \/ 392\u003c\/p\u003e \u003cp\u003e10.6 Anti-Infectious Activity \/ 394\u003c\/p\u003e \u003cp\u003e10.7 Antithrombotic Activity \/ 395\u003c\/p\u003e \u003cp\u003eSECTION 3 THERAPEUTIC NORMALIZATION OF SUBNORMAL LEVELS AND DEFECTIVE BIOLOGIC ACTIVITIES OF HDL 417\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 ENHANCEMENT OF HDL FORMATION AND NORMALIZATION OF INTRAVASCULAR HDL REMODELING 423\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11.1 Apolipoproteins \/ 423\u003c\/p\u003e \u003cp\u003e11.2 Reconstituted HDL \/ 428\u003c\/p\u003e \u003cp\u003eEffects on HDL Levels and Metabolism \/ 428\u003c\/p\u003e \u003cp\u003eEffects on HDL Functionality \/ 430\u003c\/p\u003e \u003cp\u003eRole of HDL Components \/ 432\u003c\/p\u003e \u003cp\u003e11.3 Apolipoprotein-Mimetic Peptides \/ 434\u003c\/p\u003e \u003cp\u003eEffects on HDL Levels and Metabolism \/ 434\u003c\/p\u003e \u003cp\u003eEffects on HDL Functionality \/ 434\u003c\/p\u003e \u003cp\u003e11.4 Statins \/ 440\u003c\/p\u003e \u003cp\u003eEffects on HDL Levels and Metabolism \/ 440\u003c\/p\u003e \u003cp\u003eEffects on HDL Functionality \/ 444\u003c\/p\u003e \u003cp\u003eClinical Trials \/ 446\u003c\/p\u003e \u003cp\u003e11.5 PPAR Alpha Agonists \/ 447\u003c\/p\u003e \u003cp\u003eEffects on HDL Levels \/ 447\u003c\/p\u003e \u003cp\u003eMechanisms of Action \/ 448\u003c\/p\u003e \u003cp\u003eEffects on HDL Functionality \/ 451\u003c\/p\u003e \u003cp\u003eClinical Trials \/ 452\u003c\/p\u003e \u003cp\u003e11.6 Nicotinic Acid \/ 454\u003c\/p\u003e \u003cp\u003eMechanisms of Action \/ 455\u003c\/p\u003e \u003cp\u003eClinical Trials \/ 458\u003c\/p\u003e \u003cp\u003eEffects on HDL Functionality \/ 460\u003c\/p\u003e \u003cp\u003eAdverse Effects \/ 461\u003c\/p\u003e \u003cp\u003e11.7 CETP Inhibitors \/ 463\u003c\/p\u003e \u003cp\u003eTorcetrapib \/ 464\u003c\/p\u003e \u003cp\u003eDalcetrapib \/ 467\u003c\/p\u003e \u003cp\u003eAnacetrapib \/ 467\u003c\/p\u003e \u003cp\u003eEffects on RCT \/ 469\u003c\/p\u003e \u003cp\u003eClinical Trials \/ 471\u003c\/p\u003e \u003cp\u003eEffects on HDL Functionality \/ 474\u003c\/p\u003e \u003cp\u003e11.8 Other Agents \/ 477\u003c\/p\u003e \u003cp\u003eLXR Agonists \/ 477\u003c\/p\u003e \u003cp\u003ePPAR Gamma Agonists \/ 478\u003c\/p\u003e \u003cp\u003eLipase Inhibitors \/ 479\u003c\/p\u003e \u003cp\u003e\u003ci\u003esPLA\u003c\/i\u003e2 \u003ci\u003eInhibitors \/ 480\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eEndothelial Lipase Inhibitors \/ 481\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eLpPLA\u003c\/i\u003e2 \u003ci\u003eInhibitors \/ 481\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eSR-BI Inhibitors \/ 482\u003c\/p\u003e \u003cp\u003eOthers \/ 483\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 COMBINATION THERAPIES 524\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12.1 Niacin and Statins \/ 524\u003c\/p\u003e \u003cp\u003e12.2 Fibrates and Statins \/ 527\u003c\/p\u003e \u003cp\u003e12.3 Other Combinations \/ 528\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 OTHER PHARMACOLOGIC APPROACHES 533\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e13.1 Cannabinoid Type 1 Receptor Antagonists \/ 533\u003c\/p\u003e \u003cp\u003e13.2 Estrogens \/ 536\u003c\/p\u003e \u003cp\u003e13.3 Others \/ 538\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 LIFESTYLE MODIFICATIONS 542\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14.1 Exercise \/ 542\u003c\/p\u003e \u003cp\u003e14.2 Alcohol \/ 546\u003c\/p\u003e \u003cp\u003e14.3 Nutritional Factors \/ 548\u003c\/p\u003e \u003cp\u003eDietary Fats \/ 548\u003c\/p\u003e \u003cp\u003e\u003ci\u003eCholesterol \/ 548\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePhospholipids \/ 549\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eSaturated Fatty Acids \/ 549\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eMonounsaturated Fatty Acids \/ 550\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePUFAs \/ 550\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eCarbohydrates \/ 552\u003c\/p\u003e \u003cp\u003eProteins \/ 553\u003c\/p\u003e \u003cp\u003eMinor Dietary Components \/ 554\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePolyphenols \/ 554\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eVitamins \/ 556\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eOther Minor Components \/ 556\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eCONCLUSIONS AND PERSPECTIVES 572\u003c\/p\u003e \u003cp\u003eINDEX 577\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Chemistry [\u003ca title=\"See our other books on Chemistry\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Chemistry%20%5BPN%5D%22\"\u003ePN\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52276237631768,"sku":"9780470408216","price":115.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470408216.jpg?v=1781365543","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/high-density-lipoproteins-structure-metabolism-function-and-therapeutics-hardback-9780470408216","provider":"Freshly Printed Books","version":"1.0","type":"link"}